Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 12.

Journal Article

Drilon, A., Oxnard, G. R., Tan, D. S. W., Loong, H. H. F., Johnson, M., Gainor, J., McCoach, C. E., Gautschi, O., Besse, B., Cho, B. C., Peled, N., Weiss, J., Kim, Y. -J., Ohe, Y., Nishio, M., Park, K., Patel, J., Seto, T., Sakamoto, T., Rosen, E., Shah, M. H., Barlesi, F., Cassier, P. A., Bazhenova, L., De Braud, F., Garralda, E., Velcheti, V., Satouchi, M., Ohashi, K., Pennell, N. A., Reckamp, K. L., Dy, G. K., Wolf, J., Solomon, B., Falchook, G., Ebata, K., Nguyen, M., Nair, B., Zhu, E. Y., Yang, L., Huang, X., Olek, E., Rothenberg, S. M., Goto, K. and Subbiah, V. (2020). Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med., 383 (9). S. 813 - 825. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

Dziadziuszko, R., Siena, S., Tan, D. S. W., Cho, B. C., Ahn, M-J., Goto, K., Garrido-Lopez, P., Farago, A. F., Loong, H. H. F., Tosi, D., John, T., Wolf, J., Chiu, C-H., Liu, S. V., Patel, M. R., Drilon, A., Pitcher, B., Simmons, B. and Doebele, R. C. (2020). Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline. Ann. Oncol., 31. S. S833 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Felip, E., Minotti, V., Soo, R., Wolf, J., Solomon, B., Tan, D. S. W., Ardizzoni, A., Lee, D. H., Sequist, L. V., Barlesi, F., Paz-Ares, L., Rodriguez-Abreu, D., Garcia Campelo, M. R., Sprauten, M., Djentuh, L. O'Sullivan, Belli, R., Glaser, S., Zou, M., Giovannini, M. and Yang, J. C-H. (2020). MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer. Ann. Oncol., 31. S. S829 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Heist, R. S., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Tanriverdi, O., Robeva, A., Le Mouhaer, S., Carbini, M., Agostinho, A. Chassot and Wolf, J. (2021). Capmatinib safety update in MET dysregulated NSCLC from the GEOMETRY mono-1 trial. Ann. Oncol., 32. S. S986 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Heist, R. S., Garon, E. B., Tan, D. S. W., Groen, H. J. M., Seto, T., Smit, E. F., Nwana, N., Fairchild, L., Balbin, A., Yan, M., Wang, I., Giovannini, M., Sankaran, B. and Wolf, J. (2020). Accurate Detection of METex14 Mutations in Non-Small Cell Lung Cancer (NSCLC) with Comprehensive Genomic Sequencing: Results from the GEOMETRY Mono-1 Study. J. Thorac. Oncol., 15 (2). S. S30 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

Kim, D., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., Riely, G. J., Solomon, B. J., Wolf, J., Thomas, M., Schuler, M., Liu, G., Santoro, A., Geraldes, M., Boral, A. L., Yovine, A. and Shaw, A. T. (2014). Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1. Int. J. Radiat. Oncol. Biol. Phys., 90. S. S33 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-355X

Wolf, J., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Robeva, A., Le Mouhaer, S., Carbini, M., Yovine, A. and Heist, R. (2022). Capmatinib in treatment (Tx)-naive MET exon 14-mutated (METex14) advanced non-small cell lung Cancer (aNSCLC): Updated results from GEOMETRY mono-1. Ann. Oncol., 33. S. S42 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Wolf, J., Groen, H. J. M., Akerley, W., Souquet, P. -J., Laack, E., Han, J. -Y., Smit, E. F., Mansfield, A. S., Garon, E. B., Tan, D. S. W., Heist, R. S., Waldron-Lynch, M., Le Mouhaer, S., Nwana, N., Giovannini, M. and Orlov, S. (2020). Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small- cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study. Oncol. Res. Treat., 43 (SUPPL 4). S. 143 - 144. BASEL: KARGER. ISSN 2296-5262

Wolf, J., Groen, H. J. M., Tan, D. S. W., Garon, E. B., Demanse, D., Robeva, A., Yovine, A., Fairchild, L., Boran, A. D. and Heist, R. (2022). Response to capmatinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) and MET exon 14 skipping (METex14) mutation: Whole transcriptome analysis from phase II GEOMETRY Mono-1 study. Ann. Oncol., 33 (7). S. S1003 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Wolf, J., Han, J., Nishio, M., Souquet, P., Paz-Ares, L., De Marinis, F., Seto, T., De Jonge, M., Kim, T. M., Vansteenkiste, J., Tan, D. S. W., Garon, E. B., Groen, H., Hochmair, M. J., Felip, E., Reguart, N., Thomas, M., Overbeck, T., Ohashi, K., Giovannini, M., Yura, R., Joshi, A., Akimov, M. and Heist, R. (2017). GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR wt, MET-dysregulated Advanced NSCLC. J. Thorac. Oncol., 12 (11). S. S1578 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

Wolf, J., Overbeck, T., Han, J. -Y., Hochmair, M., De Marinis, F., Ohashi, K., Smit, E. F., Power, D., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Waldron-Lynch, M., Le Mouhaer, S., Nwana, N., Giovannini, M. and Heist, R. S. (2020). Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study. Oncol. Res. Treat., 43 (SUPPL 4). S. 150 - 152. BASEL: KARGER. ISSN 2296-5262

Wolf, J., Seto, T., Han, J. Y., Reguart, N., Garon, E. B., Groen, H. J., Tan, D. S. W., Hida, T., de Jonge, M., Orlov, S., V, Smit, E. F., Souquet, P., Vansteenkiste, J., Le Mouhaer, S., Robeva, A., Waldron-Lynch, M., Balbin, A., Fairchild, L., Giovannini, M. and Heist, R. S. (2020). Capmatinib (INC280) in patients (pts) with METex14-mutated advances NSCLC: an update from phase 2 GEOMETRY mono-1 study. Pneumologie, 74. S. S134 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790

This list was generated on Thu Mar 28 15:05:56 2024 CET.